BB BIOTECH AG 13D and 13G filings for Agios Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 06:07 am Sale | 2023-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | BB BIOTECH AG | 4,000,000 7.200% | -30,792 (-0.76%) | Filing |
| 2023-02-14 4:10 pm Sale | 2022-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | BB BIOTECH AG | 4,030,792 7.300% | -281,500 (-6.53%) | Filing |
| 2022-02-11 4:51 pm Purchase | 2021-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | BB BIOTECH AG | 4,312,292 7.900% | 153,390 (+3.69%) | Filing |
| 2021-02-12 4:11 pm Purchase | 2020-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | BB BIOTECH AG | 4,158,902 6.000% | 261,948 (+6.72%) | Filing |
| 2020-02-14 2:35 pm Purchase | 2019-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | BB BIOTECH AG | 3,896,954 5.700% | 918,820 (+30.85%) | Filing |